Arcellx FDA partial clinical hold lifted for iMMagine-1; Q2 net loss $23.9M

Arcellx, Inc.

FDA lifted partial clinical hold on CART-ddBCMA Phase 2 iMMagine-1 trial after patient death and protocol modifications.
Cash, cash equivalents, and marketable securities $506.5M; funds operations through BLA filing into 2026.
Collaboration revenue of $14.3M from Kite partnership; R&D expenses $28.3M, G&A $15.5M.
Net loss improved to $23.9M vs $30.8M in Q2 2022; preliminary iMMagine-1 data expected 2H 2024.
Expanded bridging therapies allowed under revised protocol; all 17 previously enrolled patients dosed during hold.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcellx, Inc. reported second quarter ended June 30, 2023 results: revenue $14.3 million, net income $23.9 million.

Period: second quarter ended June 30, 2023
Revenue: $14.3 million
Net income: $23.9 million
Result: reported results

Exact text from the filing

Collaboration revenue was $14.3 million and $0 for the quarters ended June 30, 2023 and 2022, respectively.

View on SEC.gov

Browse all earnings releases →

Arcellx, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-042390

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.